Evidence map›Paper›PMID 42665434›Full record

Trial reportAmerican journal of hematology2026

HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities.

Halima Bello-Manga, Shehu Umar Abdullahi, Hoda Hassab, Biobele Brown, Videlis Nduba, Jessie Githanga, Adeseye Michael Akinsete, Amal El-Beshlawy, Diana Hanna, Catherine Segbefia and 16 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Halima Bello-MangaBarau Dikko Teaching Hospital, Kaduna State University, Kaduna, Nigeria.ORCID https://orcid.org/0000-0001-9993-4548
Shehu Umar AbdullahiAminu Kano Teaching Hospital, Bayero University, Kano, Nigeria.
Hoda HassabFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Biobele BrownUniversity of Ibadan, Ibadan, Nigeria.
Videlis NdubaCentre for Clinical Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.ORCID https://orcid.org/0000-0002-2266-8349
Jessie GithangaUniversity of Nairobi, Nairobi, Kenya.
Adeseye Michael AkinseteCollege of Medicine, University of Lagos, Lagos, Nigeria.ORCID https://orcid.org/0000-0002-0673-8511
Amal El-BeshlawyCairo University, Giza, Egypt.
Diana HannaZagazig University, Zagazig, Egypt.ORCID https://orcid.org/0000-0002-8967-273X
Catherine SegbefiaUniversity of Ghana Medical School, Accra, Ghana.ORCID https://orcid.org/0009-0007-4030-418X
Iheanyi OkpalaUniversity of Nigeria Teaching Hospital, Ituku-Ozalla, Nigeria.
Azza TantawyAin Shams University, Cairo, Egypt.
Bernhards OgutuCentre for Clinical Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Venée N TubmanTexas Children's Hospital, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-5973-8507
Vivian PaintsilKwame Nkrumah University of Science and Technology, Kumasi, Ghana.ORCID https://orcid.org/0000-0002-8965-0549
Yasser WaliCollege of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.ORCID https://orcid.org/0000-0003-4275-4524
Mohammed EssaKing Abdullah Specialist Children's Hospital, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Ministry of National Guard, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0003-4860-0796
Paul TelferRoyal London Hospital, Barts Health NHS Trust, London, UK.ORCID https://orcid.org/0000-0002-6895-9184
Sandy DixonPfizer Inc, New York, New York, USA.
Anne HickmanPfizer Inc, Groton, Connecticut, USA.
Jennifer F DossPfizer Inc, New York, New York, USA.
Mark W DavisPfizer Inc, New York, New York, USA.
Jeremy RuponPfizer Inc, Collegeville, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-8751-3834
Fenella J KirkhamUniversity College London, London, UK.ORCID https://orcid.org/0000-0002-2443-7958
R Clark BrownPfizer Inc, New York, New York, USA.ORCID https://orcid.org/0000-0003-0674-0213
HOPE Kids 2 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double-blind, placebo-controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ

Indexed as

Anemia, Sickle CellBenzaldehydesCerebrovascular CirculationPyrazinesPyrazolesAdolescentBlood Flow VelocityChildChild, PreschoolDouble-Blind MethodFemaleHumansMaleBenzaldehydesPyrazinesPyrazolesvoxelotor

Identifiers

PMID42665434
PMCPMC13656884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.